Latin America continues to dominate this region, with Mexico and Brazil being the most significant contributors to the region’s performance. There is one manufacturing site in this region which is situated in Brazil and which focuses on finished dose form (“FDF”). The region commercialises internationally recognised medicines across the prescription, hospital and over-the-counter (“OTC”) channels.
|Milk of Magnesia||Antacids-antiflatulants|
NUMBER OF PERMANENT EMPLOYEES
Number of products launched:
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
|Regional Brands||2 856||2 636||8|
|Sterile Focus Brands||1 439||1 400||3|
|Total||4 295||4 036||6|
Note: Commercial Pharmaceuticals revenue is by customer geography.
- The Mexican pharmaceutical market grew 8% to EUR9,01 billion MAT June 2022, positively impacted by growth across the generic, ethical and OTC markets.
- Pharmaceutical sales across the total Spanish Latin America market grew 13,6% to EUR22,5 billion MAT June 2022.
Source: IQVIA – June 2022
MAT= Moving annual total